GlobeNewswire: Generex Biotechnology Corp. Contains the last 10 of 232 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:19:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/04/18/1806755/0/en/Generex-Biotechnology-Subsidiary-Olaregen-Therapeutix-Sponsors-Prestigious-Diabetic-Limb-Salvage-Conference-in-Washington-D-C.html?f=22&fvtc=4&fvtv=6894Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors Prestigious Diabetic Limb Salvage Conference in Washington D.C.2019-04-18T17:08:33Z<![CDATA[Inventor Dr. Lois Chandler, PhD Presents Excellagen® Clinical Trial Data Demonstrating Rapid Healing of Diabetic Neuropathic Foot Ulcers]]>https://www.globenewswire.com/news-release/2019/04/08/1799088/0/en/Generex-Biotechnology-Corporation-Appoints-Mark-J-Prioletti-to-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=6894Generex Biotechnology Corporation Appoints Mark J. Prioletti to the Board of Directors2019-04-08T13:00:00Z<![CDATA[Sales & Marketing Executive Brings Global Expertise in Global Channel Marketing]]>https://www.globenewswire.com/news-release/2019/04/04/1797352/0/en/Generex-Addresses-Shareholder-Concern-Over-8-K-and-Quarterly-Filing.html?f=22&fvtc=4&fvtv=6894Generex Addresses Shareholder Concern Over 8-K and Quarterly Filing2019-04-04T19:35:42Z<![CDATA[MIRAMAR, FL, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex would like to clarify the discussions surrounding the filed 10-Q ending the period of January 31, 2019, or the second quarter, filed on March 25, 2019, and its subsequent non-reliance 8-K filed on March 28, 2019.]]>https://www.globenewswire.com/news-release/2019/03/29/1788433/0/en/Upmarket-Deal-at-2-50-Per-Share-Saves-Generex-Biotechnology-Shareholders-14-Million.html?f=22&fvtc=4&fvtv=6894Upmarket Deal at $2.50 Per Share Saves Generex Biotechnology Shareholders $14+ Million2019-03-29T13:00:00Z<![CDATA[Generex and Veneto Holdings Re-Negotiate Acquisition from a $35 Million Total Consideration to a $21 Million Stock-Only Transaction at $2.50 Per Share to Satisfy Generex’ Obligations]]>https://www.globenewswire.com/news-release/2019/03/26/1768317/0/en/Generex-Biotechnology-Partner-Olaregen-Therapeutix-Inc-Selected-to-Present-a-Formal-Poster-Session-at-Prestigious-Diabetic-Limb-Salvage-Meeting.html?f=22&fvtc=4&fvtv=6894Generex Biotechnology Partner Olaregen Therapeutix, Inc. Selected to Present a Formal Poster Session at Prestigious Diabetic Limb Salvage Meeting2019-03-26T13:00:00Z<![CDATA[Excellagen Clinical Trial Analysis: Rapid Healing of Diabetic Neuropathic Foot Ulcers]]>https://www.globenewswire.com/news-release/2019/03/12/1751862/0/en/Generex-Biotechnology-Announces-the-Appointment-of-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=6894Generex Biotechnology Announces the Appointment of Chief Commercial Officer2019-03-12T13:00:00Z<![CDATA[Lance Goudzwaard Appointed to Head Commercialization and Customer Relations for NuGenerex Distribution Solutions Subsidiary]]>https://www.globenewswire.com/news-release/2019/03/08/1750620/0/en/Generex-Biotechnology-Subsidiary-Olaregen-Therapeutix-Announces-the-Appointment-of-Vice-President-of-Business-Strategy.html?f=22&fvtc=4&fvtv=6894Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Appointment of Vice President of Business Strategy2019-03-08T14:00:00Z<![CDATA[Industry Veteran John P. Sentman to Lead Strategic Sales and Partnering]]>https://www.globenewswire.com/news-release/2019/03/01/1745329/0/en/Generex-Investor-Conference-Call-Now-Available-Online.html?f=22&fvtc=4&fvtv=6894Generex Investor Conference Call Now Available Online2019-03-01T14:00:00Z<![CDATA[MIRAMAR, FL, March 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the information for its investor conference call, is now available to listen and read on our website www.generex.com.]]>https://www.globenewswire.com/news-release/2019/02/26/1742408/0/en/Reminder-Investor-Conference-Call-Today-February-26-2019-Management-to-Provide-Update-on-Initiatives-Strategic-Plans-Call-in-Details.html?f=22&fvtc=4&fvtv=6894Reminder: Investor Conference Call Today, February 26, 2019; Management to Provide Update on Initiatives & Strategic Plans, Call-in Details2019-02-26T13:00:00Z<![CDATA[MIRAMAR, FL, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer Joseph Moscato, and his management team today February 26, at 11:00 AM Eastern time:]]>https://www.globenewswire.com/news-release/2019/02/19/1734359/0/en/Generex-Biotechnology-Subsidiary-Regentys-Corporation-Receives-Approval-of-Japanese-Patent-for-Extracellular-Matrix-Hydrogel-Regentys-ECMH.html?f=22&fvtc=4&fvtv=6894Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH™)2019-02-19T14:00:00Z<![CDATA[MIRAMAR, FL, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company’s subsidiary Regentys Corporation, a clinical stage regenerative medicine company focused on the treatment of inflammatory bowel diseases such as Ulcerative Colitis (“UC”) and Crohn’s Disease, was granted a Notice of Allowance for its patent application entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy” in Japan:]]>